Guiyang Xintian Pharmaceutical Co Ltd - Asset Resilience Ratio
Guiyang Xintian Pharmaceutical Co Ltd (002873) has an Asset Resilience Ratio of 0.00% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2025)
This chart shows how Guiyang Xintian Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. Check 002873 strategic asset allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Guiyang Xintian Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 002873 stock market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥89.77K | 0.0% |
| Total Liquid Assets | CN¥89.77K | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Guiyang Xintian Pharmaceutical Co Ltd maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Guiyang Xintian Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio
Compare Guiyang Xintian Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Syndax Pharmaceuticals Inc
NASDAQ:SNDX |
Biotechnology | 46.79% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 63.47% |
|
Chengdu Kanghua Biological Products
SHE:300841 |
Biotechnology | 1.19% |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Guiyang Xintian Pharmaceutical Co Ltd (2020–2025)
The table below shows the annual Asset Resilience Ratio data for Guiyang Xintian Pharmaceutical Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.00% | CN¥96.87K ≈ $14.18K |
CN¥2.12 Billion ≈ $310.38 Million |
0.00pp |
| 2024-12-31 | 0.01% | CN¥118.68K ≈ $17.37K |
CN¥1.95 Billion ≈ $285.42 Million |
+0.00pp |
| 2023-12-31 | 0.00% | CN¥94.33K ≈ $13.80K |
CN¥1.91 Billion ≈ $279.76 Million |
0.00pp |
| 2022-12-31 | 0.01% | CN¥111.58K ≈ $16.33K |
CN¥1.84 Billion ≈ $269.81 Million |
-5.24pp |
| 2021-12-31 | 5.25% | CN¥80.00 Million ≈ $11.71 Million |
CN¥1.52 Billion ≈ $223.07 Million |
-2.43pp |
| 2020-12-31 | 7.68% | CN¥118.00 Million ≈ $17.27 Million |
CN¥1.54 Billion ≈ $224.76 Million |
-- |
About Guiyang Xintian Pharmaceutical Co Ltd
Guiyang Xintian Pharmaceutical Co.,Ltd., together with its subsidiaries, engages in the research, development, production, and sale of new traditional Chinese medicines in China. The company offers products in various dosage forms, including hard capsules, oral solutions, granules, gels, tablets, syrups, tinctures, lotions, medicated wines, and elixirs. Its products are used for the treatment of … Read more